News

Tiziana Life Sciences Ltd. announced it plans to investigate intranasal foralumab for the treatment of Long COVID. The work is supported by foralumab’s well-established role in…
Read More...

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapies (RPT), is pleased to announce the…
Read More...

PharmaLex Group, the leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced its intention to merge with Cpharm, the leading…
Read More...

Cognizant announced it is working with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to advance the speed and quality of medicinal therapy development.…
Read More...

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the clearance of…
Read More...

Panbela Therapeutics, Inc. announced that it has regained the North American rights to develop and commercialize Flynpovi (the combination of CPP-1X (eflornithine) and sulindac) in…
Read More...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has successfully discovered a potent,…
Read More...

Centogene N.V. announced it has extended its partnership with Takeda to diagnose patients with Lysosomal Storage Disorders (LSDs). Under the renewed one-year partnership agreement,…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® …
Read More...

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for a…
Read More...

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd., a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”)…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with…
Read More...

Novartis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Entresto…
Read More...

AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a…
Read More...

GSK plc and SCYNEXIS, Inc. announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the…
Read More...

Galapagos NV and NovAliX announced a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will…
Read More...

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an…
Read More...

In the lead up to World Theranostics Day this Friday, 31st March, GenesisCare, a leading global provider of integrated cancer care and research, and PreMIT, a Melbourne-based molecular…
Read More...

Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted full approval to KEYTRUDA, Merck’s anti-PD-1 therapy,…
Read More...

The Lupus Research Alliance (LRA) announced the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership bringing people with lupus…
Read More...